Glecaprevir
Clinical data | |
---|---|
Trade names | Mavyret (combination with pibrentasvir) |
Other names | ABT-493 |
Routes of administration | By mouth |
ATC code |
|
Pharmacokinetic data | |
Protein binding | 97.5% |
Metabolism | CYP3A |
Elimination half-life | 6 hours |
Excretion | Faeces (92.1%), urine (0.7%) |
Identifiers | |
| |
JSmol) | |
| |
|
Glecaprevir (
NS5A inhibitor pibrentasvir. Together they demonstrated potent antiviral activity against major HCV genotypes and high barriers to resistance in vitro.[3]
On 19 December 2016, AbbVie submitted a
new drug application to the U.S. Food and Drug Administration for the glecaprevir/pibrentasvir (trade name Mavyret) regimen for the treatment of all major genotypes (1–6) of chronic hepatitis C. On 3 August 2017 the FDA approved the combination for hepatitis C treatment.[4] In Europe, it was approved on 17 August 2017 for the same indication, under the trade name Maviret.[5]
See also
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 76" (PDF). World Health Organization. p. 503. Retrieved 25 February 2017.
- ^ Notman, Nina (August 14, 2023). "ACS names its 2023 Heroes of Chemistry". Chemical & Engineering News. Vol. 101, no. 26. Archived from the original on 2024-03-16. Retrieved 2024-04-04.
- PMID 26711747.
- ^ "AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C." AbbVie Inc. North Chicago, Illinois, U.S.A. December 19, 2016. Retrieved 25 February 2017.
- ^ "Maviret: EPAR – Summary for the public" (PDF). European Medicines Agency. 2017-08-17.